Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674889 | 0.86 | KDM4E (0.58) | SMN1; SMN2KDM4EHSD17B10TSHRHTT | |
| SCHEMBL15456925 | 0.86 | KDM4E (0.58) | SMN1; SMN2KDM4EHSD17B10TSHRHTT | |
| SCHEMBL9535456 | 0.84 | AKR1C3 (0.60) | SMN1; SMN2ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL16569780 | 0.81 | KDM4E (0.59) | SMN1; SMN2KDM4EHSD17B10TSHRHTT | |
| SCHEMBL1474880 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL5947406 | 0.80 | KDM4E (0.57) | SMN1; SMN2KDM4EHSD17B10TSHRHTT | |
| SCHEMBL2738026 | 0.80 | ALDH1A1 (0.63) | SMN1; SMN2KDM4EHSD17B10TSHRHTT | |
| SCHEMBL7691533 | 0.80 | KDM4E (0.57) | SMN1; SMN2KDM4EHSD17B10TSHRHTT | |
| SCHEMBL2738019 | 0.79 | KDM4E (0.56) | SMN1; SMN2KDM4EHSD17B10TSHRHTT | |
| SCHEMBL5328997 | 0.78 | NEU3 (0.57) | SMN1; SMN2KDM4EHSD17B10HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1858865-B1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2009-09-16 | — | — | EP | disclosed |
| US-7566739-B2 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1861359-A1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1858865-A1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER INC. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006097817-A9 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC (JP) | 2006-12-07 | — | — | WO | disclosed |
| EP-1658265-A4 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRUENENTHAL GMBH (DE) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258884-A1 | 4-(Methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006097817-A1 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006095263-A1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER, INC. | 2006-09-14 | — | — | US | disclosed |
| EP-1658265-A1 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Grünenthal GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005003084-A1 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRUNENTHAL GMBH (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258884-A1 | 4-(Methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | TRPV1, TRPA1, GPR68 | SMN1; SMN2 231/4885KDM4E 765/4885HSD17B10 4505/4885 |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | SMN1; SMN2 3171/4885KDM4E 4595/4885HSD17B10 2121/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | SMN1; SMN2 3122/4885KDM4E 4651/4885HSD17B10 2159/4885 |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | SMN1; SMN2 2207/4885KDM4E 4075/4885HSD17B10 3107/4885 |
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | CNR1, HVCN1, AVPR1A | SMN1; SMN2 3396/4885KDM4E 4820/4885HSD17B10 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.